| Literature DB >> 33992729 |
Aleksandra Kukla1, Pedro Ventura-Aguiar2, Matthew Cooper3, Eelco J P de Koning4, David J Goodman5, Paul R Johnson6, Duck J Han7, Didier A Mandelbrot8, Martha Pavlakis9, Frantisek Saudek10, Marie-Christine Vantyghem11, Titus Augustine12, Michael R Rickels13.
Abstract
Optimal glycemic control in kidney transplant recipients with diabetes is associated with improved morbidity and better patient and allograft survival. Transplant options for patients with diabetes requiring insulin therapy and chronic kidney disease who are suitable candidates for kidney transplantation should include consideration of β-cell replacement therapy: pancreas or islet transplantation. International variation related to national regulatory policies exists in offering one or both options to suitable candidates and is further affected by pancreas/islet allocation policies and transplant waiting list dynamics. The selection of appropriate candidates depends on patient age, coexistent morbidities, the timing of referral to the transplant center (predialysis versus on dialysis) and availability of living kidney donors. Therefore, early referral (estimated glomerular filtration rate < 30 mL/min/1.73 m2) is of the utmost importance to ensure adequate time for informed decision making and thorough pretransplant evaluation. Obesity, cardiovascular disease, peripheral vascular disease, smoking, and frailty are some of the conditions that need to be addressed before acceptance on the transplant list, and ideally before dialysis becoming imminent. This review offers insights into selection of pancreas/islet transplant candidates by transplant centers and an update on posttransplant outcomes, which may have practice implications for referring nephrologists.Entities:
Keywords: chronic kidney disease (CKD); diabetes mellitus; hypoglycemia unawareness; kidney transplantation; pancreas after kidney transplantation (PAK); review; simultaneous islet-kidney transplantation (SIK); simultaneous pancreas-kidney transplantation (SPK); β-cell replacement therapy
Mesh:
Year: 2021 PMID: 33992729 PMCID: PMC8606031 DOI: 10.1053/j.ajkd.2021.02.339
Source DB: PubMed Journal: Am J Kidney Dis ISSN: 0272-6386 Impact factor: 11.072